Virtual Clinical Trials Find Bigger Voice As COVID-19 Forces Pharma Rethink
BY ASHLEY YEO Executive Summary The use of virtual, realtime and at-home testing to provide clinical trials data has been steadily gaining the interest of the health care industry. COVID-19 has put this opportunity into sharper focus, says CNS trials technology developer Cambridge Cognition, which is now adding a voice option to its portfolio.
18 / September 2020
The adjustments to normal life and business practices brought about by COVID-19 have reached into every niche, the effects in some areas being more immediately obvious than in others. The consequences are potentially far-reaching for developers of modern health care solutions. With the closing-off of some activities in the inpatient sector and the refocusing of hospital activity firmly on COVID-19 control measures, routine work on clinical trials has either halted or become severely restricted. And just as the true value and potential of telehealth and remote patient care to assuring safe and high quality care has been demonstrated during the pandemic, so virtual clinical trials are getting a showcase that was unanticipated Ěś but is proving to be highly useful.
Š Informa UK Ltd 2020 (Unauthorized photocopying prohibited.)
